When Cyltezo Isn't Available, You Still Have Options

If you rely on Cyltezo (Adalimumab-adbm) to manage a chronic autoimmune condition and your pharmacy can't fill your prescription, the anxiety is real. Missing doses of a TNF blocker can trigger disease flares, undo months of progress, and leave you in pain. But here's the important thing to know: Cyltezo is one of many adalimumab products available in the U.S., and there are solid alternatives that work the same way.

Before you panic, talk to your doctor. Switching between adalimumab products is generally safe and straightforward — especially since they all target the same protein (TNF-α) and are approved for the same conditions. Let's walk through your options.

What Is Cyltezo and How Does It Work?

Cyltezo is an interchangeable biosimilar to Humira (Adalimumab), the blockbuster biologic that dominated the autoimmune treatment market for nearly two decades. Like Humira, Cyltezo works by blocking TNF-alpha, a protein your immune system overproduces when you have an autoimmune condition. By blocking TNF-α, Cyltezo reduces the inflammation that causes joint pain, skin lesions, digestive symptoms, and other problems.

Cyltezo is FDA-approved for nine conditions:

• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
• Plaque psoriasis
• Hidradenitis suppurativa
• Juvenile idiopathic arthritis
• Uveitis

It's manufactured by Boehringer Ingelheim and was the first biosimilar to earn FDA interchangeable status with Humira. It's citrate-free and available as a pen or prefilled syringe. For a full overview, see What Is Cyltezo?

Why You Might Need an Alternative

There are several reasons you might find yourself looking for a Cyltezo alternative:

• Your pharmacy doesn't stock it. With over 10 adalimumab biosimilars on the market, most pharmacies carry only one or two. Cyltezo can be hard to find at certain pharmacies.
• Your insurance doesn't cover it. Some insurance plans and PBMs prefer a different biosimilar. If Cyltezo isn't on your formulary, you'll face higher costs or need prior authorization.
• You're experiencing side effects. While rare, some patients tolerate one adalimumab formulation better than another, particularly regarding injection site reactions.
• Cost concerns. Even among biosimilars, your out-of-pocket cost can vary based on which product your insurance prefers. Savings programs may be more generous for one product over another.

Adalimumab Biosimilar Alternatives to Cyltezo

All of the following medications contain adalimumab (or a biosimilar version of it) and work by the same mechanism — blocking TNF-α. They are approved for the same or very similar conditions as Cyltezo.

1. Amjevita (Adalimumab-atto)

Manufacturer: Amgen

Key details: Amjevita is one of the most widely available Humira biosimilars. It received interchangeable designation in March 2025, meaning pharmacists can substitute it for Humira in most states. It's citrate-free and available in both pen and prefilled syringe forms. Many PBMs, including Optum Rx, have placed Amjevita on their preferred formulary for 2025–2026, making it easier to find and more affordable under many insurance plans.

Cash price: Approximately $3,500–$6,900 per month without insurance, though copay programs from Amgen can reduce costs significantly.

2. Hyrimoz (Adalimumab-adaz)

Manufacturer: Sandoz

Key details: Hyrimoz is another interchangeable biosimilar to Humira. It's citrate-free and comes in autoinjector pen and prefilled syringe options. Sandoz has positioned Hyrimoz as a competitively priced option, and it is covered by many commercial and Medicare plans. Like Cyltezo, it can be substituted at the pharmacy level in most states.

Cash price: Approximately $3,900–$6,500 per month, with discount cards bringing costs down to around $1,000–$1,500 in some cases.

3. Hadlima (Adalimumab-bwwd)

Manufacturer: Organon / Samsung Bioepis

Key details: Hadlima is a biosimilar to Humira approved for the same indications. The low-concentration version contains citrate, which may cause slightly more injection-site discomfort than citrate-free options. However, a high-concentration citrate-free version is available. Hadlima is covered by several major insurance plans and PBMs.

Cash price: Approximately $4,200–$6,800 per month without insurance.

4. Humira (Adalimumab) — The Original

Manufacturer: AbbVie

Key details: Humira is the original adalimumab product that all biosimilars reference. While it's the most expensive option (cash price around $6,900–$7,800 per month), AbbVie offers a robust savings program that can bring copays down to as little as $5 per month for commercially insured patients. Some patients and providers prefer to stick with Humira due to familiarity and the manufacturer's support infrastructure.

How to Switch Safely

Switching between adalimumab products is generally safe and does not require a wash-out period. Clinical studies have shown that patients can switch between Humira and its interchangeable biosimilars without losing effectiveness or experiencing new safety concerns.

Here's what the process typically looks like:

1. Talk to your doctor. They'll write a new prescription for the alternative biosimilar.
2. Check your insurance. Make sure the new medication is covered under your plan. Your doctor's office can help with prior authorization if needed.
3. Coordinate with your pharmacy. Confirm the new product is in stock before you're due for your next dose.
4. Learn the new device. While injection pens work similarly across brands, the button mechanisms and needle covers differ slightly. Ask your pharmacist for a demonstration or watch the manufacturer's instructional video.

Final Thoughts

Not being able to find Cyltezo is frustrating, but it doesn't mean you're out of options. Amjevita, Hyrimoz, Hadlima, and Humira all target the same inflammatory pathway and treat the same conditions. Your doctor can help you find the one that's most accessible and affordable for you.

Start by checking availability with Medfinder, and talk to your provider about which alternative fits your insurance and preferences. The most important thing is that you stay on treatment — your health depends on it.